nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.662	1	CiPCiCtD
Afatinib—EGFR—Docetaxel—skin cancer	0.0658	0.314	CbGbCtD
Afatinib—ABCG2—Vismodegib—skin cancer	0.04	0.191	CbGbCtD
Afatinib—ABCG2—Vemurafenib—skin cancer	0.0316	0.151	CbGbCtD
Afatinib—ABCG2—Dactinomycin—skin cancer	0.021	0.1	CbGbCtD
Afatinib—ABCB1—Vismodegib—skin cancer	0.0144	0.0689	CbGbCtD
Afatinib—ABCG2—Fluorouracil—skin cancer	0.0142	0.0679	CbGbCtD
Afatinib—ABCG2—Docetaxel—skin cancer	0.0109	0.0518	CbGbCtD
Afatinib—ABCB1—Dactinomycin—skin cancer	0.00758	0.0362	CbGbCtD
Afatinib—ABCB1—Docetaxel—skin cancer	0.00392	0.0187	CbGbCtD
Afatinib—DYRK1A—hair follicle—skin cancer	0.00165	0.0653	CbGeAlD
Afatinib—IRAK1—hair follicle—skin cancer	0.00128	0.0508	CbGeAlD
Afatinib—ERBB2—nipple—skin cancer	0.00116	0.046	CbGeAlD
Afatinib—ERBB2—neck—skin cancer	0.00115	0.0455	CbGeAlD
Afatinib—BLK—lymphoid tissue—skin cancer	0.000879	0.0348	CbGeAlD
Afatinib—HIPK4—female reproductive system—skin cancer	0.000847	0.0336	CbGeAlD
Afatinib—LCK—nipple—skin cancer	0.000847	0.0336	CbGeAlD
Afatinib—ERBB2—connective tissue—skin cancer	0.000824	0.0326	CbGeAlD
Afatinib—ERBB4—epithelium—skin cancer	0.000782	0.031	CbGeAlD
Afatinib—ERBB2—epithelium—skin cancer	0.000782	0.031	CbGeAlD
Afatinib—ERBB2—skin of body—skin cancer	0.000744	0.0295	CbGeAlD
Afatinib—EPHA6—female reproductive system—skin cancer	0.00067	0.0265	CbGeAlD
Afatinib—PHKG2—female reproductive system—skin cancer	0.000646	0.0256	CbGeAlD
Afatinib—Aspartate aminotransferase increased—Vismodegib—skin cancer	0.000639	0.0116	CcSEcCtD
Afatinib—ERBB2—lymphoid tissue—skin cancer	0.000602	0.0239	CbGeAlD
Afatinib—ERBB2—female reproductive system—skin cancer	0.000581	0.023	CbGeAlD
Afatinib—ERBB4—female reproductive system—skin cancer	0.000581	0.023	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—skin cancer	0.00058	0.023	CbGeAlD
Afatinib—EGFR—mammalian vulva—skin cancer	0.000575	0.0228	CbGeAlD
Afatinib—EPHA6—head—skin cancer	0.00056	0.0222	CbGeAlD
Afatinib—DYRK1A—female reproductive system—skin cancer	0.000559	0.0222	CbGeAlD
Afatinib—Weight decreased—Vismodegib—skin cancer	0.000555	0.0101	CcSEcCtD
Afatinib—PHKG2—head—skin cancer	0.00054	0.0214	CbGeAlD
Afatinib—Interstitial lung disease—Bleomycin—skin cancer	0.000517	0.00942	CcSEcCtD
Afatinib—IRAK1—mammalian vulva—skin cancer	0.000507	0.0201	CbGeAlD
Afatinib—BLK—lymph node—skin cancer	0.000496	0.0196	CbGeAlD
Afatinib—LCK—mammalian vulva—skin cancer	0.000495	0.0196	CbGeAlD
Afatinib—ABL1—nipple—skin cancer	0.000487	0.0193	CbGeAlD
Afatinib—ERBB2—head—skin cancer	0.000485	0.0192	CbGeAlD
Afatinib—ERBB4—head—skin cancer	0.000485	0.0192	CbGeAlD
Afatinib—Connective tissue disorder—Vismodegib—skin cancer	0.000483	0.00879	CcSEcCtD
Afatinib—DYRK1A—head—skin cancer	0.000467	0.0185	CbGeAlD
Afatinib—Interstitial lung disease—Temozolomide—skin cancer	0.000436	0.00795	CcSEcCtD
Afatinib—IRAK1—female reproductive system—skin cancer	0.000434	0.0172	CbGeAlD
Afatinib—Alopecia—Vismodegib—skin cancer	0.000434	0.00791	CcSEcCtD
Afatinib—Malnutrition—Vismodegib—skin cancer	0.000428	0.00779	CcSEcCtD
Afatinib—Dysgeusia—Vismodegib—skin cancer	0.000419	0.00763	CcSEcCtD
Afatinib—Back pain—Vismodegib—skin cancer	0.000414	0.00753	CcSEcCtD
Afatinib—Muscle spasms—Vismodegib—skin cancer	0.000411	0.00749	CcSEcCtD
Afatinib—Dry skin—Vemurafenib—skin cancer	0.000402	0.00732	CcSEcCtD
Afatinib—PHKG2—lymph node—skin cancer	0.000378	0.015	CbGeAlD
Afatinib—Mucosal inflammation—Docetaxel—skin cancer	0.000371	0.00676	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.000361	0.00658	CcSEcCtD
Afatinib—Cystitis noninfective—Bleomycin—skin cancer	0.000358	0.00651	CcSEcCtD
Afatinib—Cystitis—Bleomycin—skin cancer	0.000353	0.00644	CcSEcCtD
Afatinib—ABL1—connective tissue—skin cancer	0.000345	0.0137	CbGeAlD
Afatinib—Weight decreased—Vemurafenib—skin cancer	0.000343	0.00625	CcSEcCtD
Afatinib—Nervous system disorder—Vismodegib—skin cancer	0.000342	0.00623	CcSEcCtD
Afatinib—ERBB2—lymph node—skin cancer	0.00034	0.0135	CbGeAlD
Afatinib—Skin disorder—Vismodegib—skin cancer	0.000339	0.00617	CcSEcCtD
Afatinib—Infestation—Vemurafenib—skin cancer	0.000338	0.00616	CcSEcCtD
Afatinib—Infestation NOS—Vemurafenib—skin cancer	0.000338	0.00616	CcSEcCtD
Afatinib—Bladder pain—Bleomycin—skin cancer	0.000331	0.00603	CcSEcCtD
Afatinib—DYRK1A—lymph node—skin cancer	0.000327	0.013	CbGeAlD
Afatinib—ABL1—skin of body—skin cancer	0.000312	0.0123	CbGeAlD
Afatinib—Mouth ulceration—Dactinomycin—skin cancer	0.000309	0.00562	CcSEcCtD
Afatinib—Dyspepsia—Vismodegib—skin cancer	0.000307	0.0056	CcSEcCtD
Afatinib—Decreased appetite—Vismodegib—skin cancer	0.000303	0.00553	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vismodegib—skin cancer	0.000301	0.00549	CcSEcCtD
Afatinib—Fatigue—Vismodegib—skin cancer	0.000301	0.00548	CcSEcCtD
Afatinib—Upper respiratory tract infection—Imiquimod—skin cancer	0.0003	0.00547	CcSEcCtD
Afatinib—Constipation—Vismodegib—skin cancer	0.000298	0.00544	CcSEcCtD
Afatinib—Connective tissue disorder—Vemurafenib—skin cancer	0.000298	0.00543	CcSEcCtD
Afatinib—Sepsis—Dactinomycin—skin cancer	0.000296	0.0054	CcSEcCtD
Afatinib—Interstitial lung disease—Docetaxel—skin cancer	0.00029	0.00529	CcSEcCtD
Afatinib—Infestation NOS—Imiquimod—skin cancer	0.000288	0.00525	CcSEcCtD
Afatinib—Infestation—Imiquimod—skin cancer	0.000288	0.00525	CcSEcCtD
Afatinib—EGFR—lymph node—skin cancer	0.000288	0.0114	CbGeAlD
Afatinib—Dry eye—Temozolomide—skin cancer	0.000285	0.0052	CcSEcCtD
Afatinib—ABL1—mammalian vulva—skin cancer	0.000284	0.0113	CbGeAlD
Afatinib—Eye disorder—Vemurafenib—skin cancer	0.000284	0.00517	CcSEcCtD
Afatinib—Conjunctivitis—Imiquimod—skin cancer	0.00028	0.0051	CcSEcCtD
Afatinib—Urinary tract infection—Imiquimod—skin cancer	0.00028	0.0051	CcSEcCtD
Afatinib—Mediastinal disorder—Vemurafenib—skin cancer	0.000273	0.00498	CcSEcCtD
Afatinib—Hepatobiliary disease—Imiquimod—skin cancer	0.000273	0.00497	CcSEcCtD
Afatinib—Alopecia—Vemurafenib—skin cancer	0.000268	0.00488	CcSEcCtD
Afatinib—Malnutrition—Vemurafenib—skin cancer	0.000264	0.00481	CcSEcCtD
Afatinib—Dysgeusia—Vemurafenib—skin cancer	0.000259	0.00471	CcSEcCtD
Afatinib—Urinary tract disorder—Imiquimod—skin cancer	0.000256	0.00466	CcSEcCtD
Afatinib—Back pain—Vemurafenib—skin cancer	0.000255	0.00465	CcSEcCtD
Afatinib—Connective tissue disorder—Imiquimod—skin cancer	0.000254	0.00463	CcSEcCtD
Afatinib—IRAK1—lymph node—skin cancer	0.000254	0.0101	CbGeAlD
Afatinib—Urethral disorder—Imiquimod—skin cancer	0.000254	0.00462	CcSEcCtD
Afatinib—Rhinorrhoea—Docetaxel—skin cancer	0.000253	0.00462	CcSEcCtD
Afatinib—ABL1—lymphoid tissue—skin cancer	0.000252	0.01	CbGeAlD
Afatinib—Asthenia—Vismodegib—skin cancer	0.00025	0.00456	CcSEcCtD
Afatinib—LCK—lymph node—skin cancer	0.000248	0.00982	CbGeAlD
Afatinib—Sepsis—Fluorouracil—skin cancer	0.000247	0.0045	CcSEcCtD
Afatinib—Pruritus—Vismodegib—skin cancer	0.000247	0.0045	CcSEcCtD
Afatinib—ABL1—female reproductive system—skin cancer	0.000243	0.00964	CbGeAlD
Afatinib—Eye disorder—Imiquimod—skin cancer	0.000242	0.00441	CcSEcCtD
Afatinib—Diarrhoea—Vismodegib—skin cancer	0.000239	0.00435	CcSEcCtD
Afatinib—Mediastinal disorder—Imiquimod—skin cancer	0.000233	0.00425	CcSEcCtD
Afatinib—Cough—Vemurafenib—skin cancer	0.00023	0.0042	CcSEcCtD
Afatinib—Alopecia—Imiquimod—skin cancer	0.000229	0.00417	CcSEcCtD
Afatinib—Mental disorder—Imiquimod—skin cancer	0.000227	0.00413	CcSEcCtD
Afatinib—Malnutrition—Imiquimod—skin cancer	0.000225	0.0041	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000223	0.00407	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.000223	0.00407	CcSEcCtD
Afatinib—Vomiting—Vismodegib—skin cancer	0.000222	0.00404	CcSEcCtD
Afatinib—Rash—Vismodegib—skin cancer	0.00022	0.00401	CcSEcCtD
Afatinib—Dermatitis—Vismodegib—skin cancer	0.00022	0.004	CcSEcCtD
Afatinib—Back pain—Imiquimod—skin cancer	0.000218	0.00397	CcSEcCtD
Afatinib—Infection—Vemurafenib—skin cancer	0.000214	0.0039	CcSEcCtD
Afatinib—Nervous system disorder—Vemurafenib—skin cancer	0.000211	0.00385	CcSEcCtD
Afatinib—Skin disorder—Vemurafenib—skin cancer	0.000209	0.00381	CcSEcCtD
Afatinib—ABCB1—blood vessel—skin cancer	0.000209	0.00829	CbGeAlD
Afatinib—Dehydration—Temozolomide—skin cancer	0.000208	0.0038	CcSEcCtD
Afatinib—Weight decreased—Bleomycin—skin cancer	0.000208	0.00379	CcSEcCtD
Afatinib—Nausea—Vismodegib—skin cancer	0.000207	0.00378	CcSEcCtD
Afatinib—Pneumonia—Bleomycin—skin cancer	0.000206	0.00375	CcSEcCtD
Afatinib—Dry skin—Temozolomide—skin cancer	0.000205	0.00374	CcSEcCtD
Afatinib—Hypokalaemia—Temozolomide—skin cancer	0.000204	0.00372	CcSEcCtD
Afatinib—ABL1—head—skin cancer	0.000203	0.00806	CbGeAlD
Afatinib—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.000202	0.00368	CcSEcCtD
Afatinib—Stomatitis—Bleomycin—skin cancer	0.0002	0.00364	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000198	0.0036	CcSEcCtD
Afatinib—Cough—Imiquimod—skin cancer	0.000197	0.00358	CcSEcCtD
Afatinib—Pneumonia—Dactinomycin—skin cancer	0.000192	0.0035	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00019	0.00347	CcSEcCtD
Afatinib—Dry skin—Fluorouracil—skin cancer	0.000189	0.00345	CcSEcCtD
Afatinib—Decreased appetite—Vemurafenib—skin cancer	0.000187	0.00341	CcSEcCtD
Afatinib—Stomatitis—Dactinomycin—skin cancer	0.000186	0.00339	CcSEcCtD
Afatinib—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000186	0.00339	CcSEcCtD
Afatinib—Fatigue—Vemurafenib—skin cancer	0.000186	0.00339	CcSEcCtD
Afatinib—Nasopharyngitis—Fluorouracil—skin cancer	0.000185	0.00336	CcSEcCtD
Afatinib—Constipation—Vemurafenib—skin cancer	0.000184	0.00336	CcSEcCtD
Afatinib—Infection—Imiquimod—skin cancer	0.000183	0.00333	CcSEcCtD
Afatinib—Nervous system disorder—Imiquimod—skin cancer	0.00018	0.00328	CcSEcCtD
Afatinib—Upper respiratory tract infection—Temozolomide—skin cancer	0.00018	0.00328	CcSEcCtD
Afatinib—ABCG2—mammalian vulva—skin cancer	0.000179	0.0071	CbGeAlD
Afatinib—Skin disorder—Imiquimod—skin cancer	0.000179	0.00325	CcSEcCtD
Afatinib—Sepsis—Docetaxel—skin cancer	0.000178	0.00325	CcSEcCtD
Afatinib—Weight decreased—Temozolomide—skin cancer	0.000175	0.00319	CcSEcCtD
Afatinib—Pneumonia—Temozolomide—skin cancer	0.000174	0.00316	CcSEcCtD
Afatinib—Infestation NOS—Temozolomide—skin cancer	0.000173	0.00315	CcSEcCtD
Afatinib—Infestation—Temozolomide—skin cancer	0.000173	0.00315	CcSEcCtD
Afatinib—Body temperature increased—Vemurafenib—skin cancer	0.00017	0.0031	CcSEcCtD
Afatinib—Stomatitis—Temozolomide—skin cancer	0.000168	0.00307	CcSEcCtD
Afatinib—Urinary tract infection—Temozolomide—skin cancer	0.000168	0.00306	CcSEcCtD
Afatinib—Insomnia—Imiquimod—skin cancer	0.000166	0.00303	CcSEcCtD
Afatinib—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000166	0.00302	CcSEcCtD
Afatinib—Dyspnoea—Imiquimod—skin cancer	0.000164	0.00299	CcSEcCtD
Afatinib—Hepatobiliary disease—Temozolomide—skin cancer	0.000163	0.00298	CcSEcCtD
Afatinib—Alopecia—Bleomycin—skin cancer	0.000162	0.00296	CcSEcCtD
Afatinib—Dyspepsia—Imiquimod—skin cancer	0.000162	0.00295	CcSEcCtD
Afatinib—Pneumonia—Fluorouracil—skin cancer	0.00016	0.00292	CcSEcCtD
Afatinib—Decreased appetite—Imiquimod—skin cancer	0.00016	0.00291	CcSEcCtD
Afatinib—Infestation NOS—Fluorouracil—skin cancer	0.000159	0.0029	CcSEcCtD
Afatinib—Infestation—Fluorouracil—skin cancer	0.000159	0.0029	CcSEcCtD
Afatinib—Gastrointestinal disorder—Imiquimod—skin cancer	0.000159	0.00289	CcSEcCtD
Afatinib—Fatigue—Imiquimod—skin cancer	0.000158	0.00289	CcSEcCtD
Afatinib—Renal impairment—Docetaxel—skin cancer	0.000157	0.00285	CcSEcCtD
Afatinib—Stomatitis—Fluorouracil—skin cancer	0.000155	0.00283	CcSEcCtD
Afatinib—Urinary tract infection—Fluorouracil—skin cancer	0.000155	0.00282	CcSEcCtD
Afatinib—Conjunctivitis—Fluorouracil—skin cancer	0.000155	0.00282	CcSEcCtD
Afatinib—Asthenia—Vemurafenib—skin cancer	0.000155	0.00282	CcSEcCtD
Afatinib—Urinary tract disorder—Temozolomide—skin cancer	0.000153	0.00279	CcSEcCtD
Afatinib—Pruritus—Vemurafenib—skin cancer	0.000153	0.00278	CcSEcCtD
Afatinib—Connective tissue disorder—Temozolomide—skin cancer	0.000152	0.00278	CcSEcCtD
Afatinib—Urethral disorder—Temozolomide—skin cancer	0.000152	0.00277	CcSEcCtD
Afatinib—Alopecia—Dactinomycin—skin cancer	0.000151	0.00276	CcSEcCtD
Afatinib—Epistaxis—Fluorouracil—skin cancer	0.00015	0.00273	CcSEcCtD
Afatinib—Diarrhoea—Vemurafenib—skin cancer	0.000147	0.00269	CcSEcCtD
Afatinib—Body temperature increased—Imiquimod—skin cancer	0.000145	0.00265	CcSEcCtD
Afatinib—Eye disorder—Temozolomide—skin cancer	0.000145	0.00264	CcSEcCtD
Afatinib—Dizziness—Vemurafenib—skin cancer	0.000143	0.0026	CcSEcCtD
Afatinib—ABL1—lymph node—skin cancer	0.000142	0.00564	CbGeAlD
Afatinib—Mediastinal disorder—Temozolomide—skin cancer	0.00014	0.00255	CcSEcCtD
Afatinib—Cough—Bleomycin—skin cancer	0.00014	0.00254	CcSEcCtD
Afatinib—Dehydration—Docetaxel—skin cancer	0.000139	0.00253	CcSEcCtD
Afatinib—Vomiting—Vemurafenib—skin cancer	0.000137	0.0025	CcSEcCtD
Afatinib—Alopecia—Temozolomide—skin cancer	0.000137	0.0025	CcSEcCtD
Afatinib—Dry skin—Docetaxel—skin cancer	0.000137	0.00249	CcSEcCtD
Afatinib—Rash—Vemurafenib—skin cancer	0.000136	0.00248	CcSEcCtD
Afatinib—Mental disorder—Temozolomide—skin cancer	0.000136	0.00247	CcSEcCtD
Afatinib—Dermatitis—Vemurafenib—skin cancer	0.000136	0.00247	CcSEcCtD
Afatinib—Headache—Vemurafenib—skin cancer	0.000135	0.00246	CcSEcCtD
Afatinib—Malnutrition—Temozolomide—skin cancer	0.000135	0.00246	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000134	0.00245	CcSEcCtD
Afatinib—Nasopharyngitis—Docetaxel—skin cancer	0.000133	0.00243	CcSEcCtD
Afatinib—Dysgeusia—Temozolomide—skin cancer	0.000132	0.00241	CcSEcCtD
Afatinib—Asthenia—Imiquimod—skin cancer	0.000132	0.0024	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000131	0.00239	CcSEcCtD
Afatinib—Back pain—Temozolomide—skin cancer	0.000131	0.00238	CcSEcCtD
Afatinib—Pruritus—Imiquimod—skin cancer	0.00013	0.00237	CcSEcCtD
Afatinib—Infection—Bleomycin—skin cancer	0.00013	0.00236	CcSEcCtD
Afatinib—Nausea—Vemurafenib—skin cancer	0.000128	0.00233	CcSEcCtD
Afatinib—Alopecia—Fluorouracil—skin cancer	0.000126	0.0023	CcSEcCtD
Afatinib—Diarrhoea—Imiquimod—skin cancer	0.000126	0.00229	CcSEcCtD
Afatinib—Dizziness—Imiquimod—skin cancer	0.000122	0.00221	CcSEcCtD
Afatinib—Infection—Dactinomycin—skin cancer	0.000121	0.0022	CcSEcCtD
Afatinib—Cough—Temozolomide—skin cancer	0.000118	0.00215	CcSEcCtD
Afatinib—Vomiting—Imiquimod—skin cancer	0.000117	0.00213	CcSEcCtD
Afatinib—Weight decreased—Docetaxel—skin cancer	0.000117	0.00212	CcSEcCtD
Afatinib—Dyspnoea—Bleomycin—skin cancer	0.000116	0.00212	CcSEcCtD
Afatinib—Rash—Imiquimod—skin cancer	0.000116	0.00211	CcSEcCtD
Afatinib—Dermatitis—Imiquimod—skin cancer	0.000116	0.00211	CcSEcCtD
Afatinib—Pneumonia—Docetaxel—skin cancer	0.000116	0.0021	CcSEcCtD
Afatinib—Headache—Imiquimod—skin cancer	0.000115	0.0021	CcSEcCtD
Afatinib—Infestation NOS—Docetaxel—skin cancer	0.000115	0.00209	CcSEcCtD
Afatinib—Infestation—Docetaxel—skin cancer	0.000115	0.00209	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000114	0.00208	CcSEcCtD
Afatinib—Decreased appetite—Bleomycin—skin cancer	0.000114	0.00207	CcSEcCtD
Afatinib—Renal failure—Docetaxel—skin cancer	0.000113	0.00206	CcSEcCtD
Afatinib—Stomatitis—Docetaxel—skin cancer	0.000112	0.00204	CcSEcCtD
Afatinib—Conjunctivitis—Docetaxel—skin cancer	0.000112	0.00203	CcSEcCtD
Afatinib—Infection—Temozolomide—skin cancer	0.000109	0.00199	CcSEcCtD
Afatinib—Nausea—Imiquimod—skin cancer	0.000109	0.00199	CcSEcCtD
Afatinib—Hepatobiliary disease—Docetaxel—skin cancer	0.000109	0.00198	CcSEcCtD
Afatinib—Epistaxis—Docetaxel—skin cancer	0.000108	0.00197	CcSEcCtD
Afatinib—Nervous system disorder—Temozolomide—skin cancer	0.000108	0.00197	CcSEcCtD
Afatinib—Skin disorder—Temozolomide—skin cancer	0.000107	0.00195	CcSEcCtD
Afatinib—Decreased appetite—Dactinomycin—skin cancer	0.000106	0.00193	CcSEcCtD
Afatinib—Fatigue—Dactinomycin—skin cancer	0.000105	0.00191	CcSEcCtD
Afatinib—Body temperature increased—Bleomycin—skin cancer	0.000103	0.00188	CcSEcCtD
Afatinib—ABCB1—epithelium—skin cancer	0.000102	0.00404	CbGeAlD
Afatinib—Urinary tract disorder—Docetaxel—skin cancer	0.000102	0.00186	CcSEcCtD
Afatinib—Connective tissue disorder—Docetaxel—skin cancer	0.000101	0.00185	CcSEcCtD
Afatinib—Urethral disorder—Docetaxel—skin cancer	0.000101	0.00184	CcSEcCtD
Afatinib—Infection—Fluorouracil—skin cancer	0.000101	0.00184	CcSEcCtD
Afatinib—Insomnia—Temozolomide—skin cancer	9.96e-05	0.00182	CcSEcCtD
Afatinib—Nervous system disorder—Fluorouracil—skin cancer	9.95e-05	0.00181	CcSEcCtD
Afatinib—Dyspnoea—Temozolomide—skin cancer	9.82e-05	0.00179	CcSEcCtD
Afatinib—Dyspepsia—Temozolomide—skin cancer	9.7e-05	0.00177	CcSEcCtD
Afatinib—Eye disorder—Docetaxel—skin cancer	9.64e-05	0.00176	CcSEcCtD
Afatinib—Body temperature increased—Dactinomycin—skin cancer	9.63e-05	0.00175	CcSEcCtD
Afatinib—Decreased appetite—Temozolomide—skin cancer	9.58e-05	0.00174	CcSEcCtD
Afatinib—Gastrointestinal disorder—Temozolomide—skin cancer	9.51e-05	0.00173	CcSEcCtD
Afatinib—Fatigue—Temozolomide—skin cancer	9.5e-05	0.00173	CcSEcCtD
Afatinib—Constipation—Temozolomide—skin cancer	9.42e-05	0.00172	CcSEcCtD
Afatinib—Asthenia—Bleomycin—skin cancer	9.37e-05	0.00171	CcSEcCtD
Afatinib—Mediastinal disorder—Docetaxel—skin cancer	9.29e-05	0.00169	CcSEcCtD
Afatinib—Pruritus—Bleomycin—skin cancer	9.24e-05	0.00168	CcSEcCtD
Afatinib—Insomnia—Fluorouracil—skin cancer	9.18e-05	0.00167	CcSEcCtD
Afatinib—Alopecia—Docetaxel—skin cancer	9.11e-05	0.00166	CcSEcCtD
Afatinib—Dyspnoea—Fluorouracil—skin cancer	9.05e-05	0.00165	CcSEcCtD
Afatinib—Mental disorder—Docetaxel—skin cancer	9.03e-05	0.00165	CcSEcCtD
Afatinib—ABCG2—lymph node—skin cancer	8.98e-05	0.00356	CbGeAlD
Afatinib—Malnutrition—Docetaxel—skin cancer	8.98e-05	0.00164	CcSEcCtD
Afatinib—Dyspepsia—Fluorouracil—skin cancer	8.93e-05	0.00163	CcSEcCtD
Afatinib—ABCB1—mammalian vulva—skin cancer	8.84e-05	0.0035	CbGeAlD
Afatinib—Decreased appetite—Fluorouracil—skin cancer	8.82e-05	0.00161	CcSEcCtD
Afatinib—Dysgeusia—Docetaxel—skin cancer	8.79e-05	0.0016	CcSEcCtD
Afatinib—Gastrointestinal disorder—Fluorouracil—skin cancer	8.76e-05	0.0016	CcSEcCtD
Afatinib—Asthenia—Dactinomycin—skin cancer	8.74e-05	0.00159	CcSEcCtD
Afatinib—Body temperature increased—Temozolomide—skin cancer	8.71e-05	0.00159	CcSEcCtD
Afatinib—Back pain—Docetaxel—skin cancer	8.68e-05	0.00158	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—skin cancer	8.63e-05	0.00157	CcSEcCtD
Afatinib—Diarrhoea—Dactinomycin—skin cancer	8.33e-05	0.00152	CcSEcCtD
Afatinib—Vomiting—Bleomycin—skin cancer	8.3e-05	0.00151	CcSEcCtD
Afatinib—Rash—Bleomycin—skin cancer	8.23e-05	0.0015	CcSEcCtD
Afatinib—Dermatitis—Bleomycin—skin cancer	8.23e-05	0.0015	CcSEcCtD
Afatinib—Body temperature increased—Fluorouracil—skin cancer	8.02e-05	0.00146	CcSEcCtD
Afatinib—Asthenia—Temozolomide—skin cancer	7.9e-05	0.00144	CcSEcCtD
Afatinib—ABCB1—lymphoid tissue—skin cancer	7.85e-05	0.00311	CbGeAlD
Afatinib—Cough—Docetaxel—skin cancer	7.83e-05	0.00143	CcSEcCtD
Afatinib—Pruritus—Temozolomide—skin cancer	7.79e-05	0.00142	CcSEcCtD
Afatinib—Nausea—Bleomycin—skin cancer	7.76e-05	0.00141	CcSEcCtD
Afatinib—Vomiting—Dactinomycin—skin cancer	7.74e-05	0.00141	CcSEcCtD
Afatinib—Rash—Dactinomycin—skin cancer	7.68e-05	0.0014	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	7.59e-05	0.00138	CcSEcCtD
Afatinib—ABCB1—female reproductive system—skin cancer	7.57e-05	0.003	CbGeAlD
Afatinib—Diarrhoea—Temozolomide—skin cancer	7.54e-05	0.00137	CcSEcCtD
Afatinib—Dizziness—Temozolomide—skin cancer	7.28e-05	0.00133	CcSEcCtD
Afatinib—Infection—Docetaxel—skin cancer	7.28e-05	0.00133	CcSEcCtD
Afatinib—Nausea—Dactinomycin—skin cancer	7.23e-05	0.00132	CcSEcCtD
Afatinib—Nervous system disorder—Docetaxel—skin cancer	7.18e-05	0.00131	CcSEcCtD
Afatinib—Pruritus—Fluorouracil—skin cancer	7.18e-05	0.00131	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—skin cancer	7.12e-05	0.0013	CcSEcCtD
Afatinib—Vomiting—Temozolomide—skin cancer	7e-05	0.00128	CcSEcCtD
Afatinib—Rash—Temozolomide—skin cancer	6.95e-05	0.00127	CcSEcCtD
Afatinib—Diarrhoea—Fluorouracil—skin cancer	6.94e-05	0.00127	CcSEcCtD
Afatinib—Dermatitis—Temozolomide—skin cancer	6.94e-05	0.00126	CcSEcCtD
Afatinib—Headache—Temozolomide—skin cancer	6.9e-05	0.00126	CcSEcCtD
Afatinib—Dizziness—Fluorouracil—skin cancer	6.71e-05	0.00122	CcSEcCtD
Afatinib—Insomnia—Docetaxel—skin cancer	6.63e-05	0.00121	CcSEcCtD
Afatinib—Nausea—Temozolomide—skin cancer	6.54e-05	0.00119	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—skin cancer	6.53e-05	0.00119	CcSEcCtD
Afatinib—Vomiting—Fluorouracil—skin cancer	6.45e-05	0.00118	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—skin cancer	6.45e-05	0.00117	CcSEcCtD
Afatinib—Rash—Fluorouracil—skin cancer	6.4e-05	0.00117	CcSEcCtD
Afatinib—Dermatitis—Fluorouracil—skin cancer	6.39e-05	0.00116	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—skin cancer	6.37e-05	0.00116	CcSEcCtD
Afatinib—Headache—Fluorouracil—skin cancer	6.36e-05	0.00116	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—skin cancer	6.32e-05	0.00115	CcSEcCtD
Afatinib—ABCB1—head—skin cancer	6.32e-05	0.0025	CbGeAlD
Afatinib—Fatigue—Docetaxel—skin cancer	6.32e-05	0.00115	CcSEcCtD
Afatinib—Constipation—Docetaxel—skin cancer	6.26e-05	0.00114	CcSEcCtD
Afatinib—Nausea—Fluorouracil—skin cancer	6.03e-05	0.0011	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—skin cancer	5.79e-05	0.00106	CcSEcCtD
Afatinib—Asthenia—Docetaxel—skin cancer	5.26e-05	0.000958	CcSEcCtD
Afatinib—Pruritus—Docetaxel—skin cancer	5.18e-05	0.000944	CcSEcCtD
Afatinib—Diarrhoea—Docetaxel—skin cancer	5.01e-05	0.000913	CcSEcCtD
Afatinib—Dizziness—Docetaxel—skin cancer	4.84e-05	0.000883	CcSEcCtD
Afatinib—Vomiting—Docetaxel—skin cancer	4.66e-05	0.000849	CcSEcCtD
Afatinib—Rash—Docetaxel—skin cancer	4.62e-05	0.000842	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—skin cancer	4.61e-05	0.000841	CcSEcCtD
Afatinib—Headache—Docetaxel—skin cancer	4.59e-05	0.000836	CcSEcCtD
Afatinib—ABCB1—lymph node—skin cancer	4.43e-05	0.00175	CbGeAlD
Afatinib—Nausea—Docetaxel—skin cancer	4.35e-05	0.000793	CcSEcCtD
Afatinib—IRAK1—Signaling by NGF—HRAS—skin cancer	1.25e-05	0.000257	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTGER4—skin cancer	1.25e-05	0.000257	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—IL6—skin cancer	1.25e-05	0.000257	CbGpPWpGaD
Afatinib—LCK—Disease—SHH—skin cancer	1.25e-05	0.000256	CbGpPWpGaD
Afatinib—LCK—Disease—ENO2—skin cancer	1.25e-05	0.000256	CbGpPWpGaD
Afatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	1.24e-05	0.000255	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.24e-05	0.000254	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	1.24e-05	0.000253	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	1.23e-05	0.000252	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—HRAS—skin cancer	1.23e-05	0.000252	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—HRAS—skin cancer	1.23e-05	0.000252	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—NRAS—skin cancer	1.23e-05	0.000252	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MC1R—skin cancer	1.23e-05	0.000252	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—IL6—skin cancer	1.22e-05	0.000251	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IL6—skin cancer	1.22e-05	0.00025	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—HRAS—skin cancer	1.22e-05	0.00025	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—IL6—skin cancer	1.22e-05	0.00025	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—NRAS—skin cancer	1.21e-05	0.000249	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—IL6—skin cancer	1.21e-05	0.000248	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.21e-05	0.000248	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GLI1—skin cancer	1.21e-05	0.000248	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—HRAS—skin cancer	1.21e-05	0.000248	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—IL6—skin cancer	1.21e-05	0.000247	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—HRAS—skin cancer	1.2e-05	0.000247	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—IL6—skin cancer	1.2e-05	0.000246	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SUFU—skin cancer	1.19e-05	0.000244	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	1.19e-05	0.000243	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—HRAS—skin cancer	1.19e-05	0.000243	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—HRAS—skin cancer	1.19e-05	0.000243	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	1.18e-05	0.000241	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—IL6—skin cancer	1.18e-05	0.000241	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—IL6—skin cancer	1.18e-05	0.000241	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—HRAS—skin cancer	1.17e-05	0.000241	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—IL6—skin cancer	1.17e-05	0.000239	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—HRAS—skin cancer	1.16e-05	0.000239	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—KRAS—skin cancer	1.16e-05	0.000238	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—HRAS—skin cancer	1.16e-05	0.000238	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—HRAS—skin cancer	1.16e-05	0.000238	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—IL6—skin cancer	1.16e-05	0.000237	CbGpPWpGaD
Afatinib—ERBB2—Disease—BRAF—skin cancer	1.16e-05	0.000237	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—IL6—skin cancer	1.15e-05	0.000236	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SUFU—skin cancer	1.15e-05	0.000235	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—KRAS—skin cancer	1.15e-05	0.000235	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—NRAS—skin cancer	1.15e-05	0.000235	CbGpPWpGaD
Afatinib—EGFR—Immune System—FOXO4—skin cancer	1.14e-05	0.000235	CbGpPWpGaD
Afatinib—ERBB4—Disease—BRAF—skin cancer	1.14e-05	0.000234	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—HRAS—skin cancer	1.14e-05	0.000233	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—IL6—skin cancer	1.13e-05	0.000233	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	1.13e-05	0.000233	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—IL6—skin cancer	1.13e-05	0.000233	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—IL6—skin cancer	1.12e-05	0.000231	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—NRAS—skin cancer	1.12e-05	0.00023	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—HRAS—skin cancer	1.12e-05	0.00023	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—KRAS—skin cancer	1.12e-05	0.000229	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—IL6—skin cancer	1.11e-05	0.000229	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—IL6—skin cancer	1.11e-05	0.000228	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FOXO4—skin cancer	1.11e-05	0.000227	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—NRAS—skin cancer	1.1e-05	0.000226	CbGpPWpGaD
Afatinib—LCK—Immune System—FOXO4—skin cancer	1.1e-05	0.000226	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—KRAS—skin cancer	1.1e-05	0.000226	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—HRAS—skin cancer	1.1e-05	0.000225	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.09e-05	0.000223	CbGpPWpGaD
Afatinib—PHKG2—Disease—HRAS—skin cancer	1.07e-05	0.00022	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—IL6—skin cancer	1.07e-05	0.00022	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—KRAS—skin cancer	1.06e-05	0.000217	CbGpPWpGaD
Afatinib—EGFR—Disease—FOXO4—skin cancer	1.06e-05	0.000217	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.05e-05	0.000216	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.05e-05	0.000215	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—KRAS—skin cancer	1.04e-05	0.000214	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1.04e-05	0.000214	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—NRAS—skin cancer	1.04e-05	0.000213	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.03e-05	0.00021	CbGpPWpGaD
Afatinib—PHKG2—Disease—IL6—skin cancer	1.03e-05	0.00021	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TERT—skin cancer	1.02e-05	0.00021	CbGpPWpGaD
Afatinib—LCK—Disease—FOXO4—skin cancer	1.02e-05	0.000209	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ENO2—skin cancer	1.01e-05	0.000208	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.01e-05	0.000207	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TERT—skin cancer	1.01e-05	0.000207	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1e-05	0.000206	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLIN2—skin cancer	1e-05	0.000205	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HRAS—skin cancer	9.89e-06	0.000203	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—KRAS—skin cancer	9.86e-06	0.000202	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—NRAS—skin cancer	9.77e-06	0.0002	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HRAS—skin cancer	9.74e-06	0.0002	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—KRAS—skin cancer	9.66e-06	0.000198	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—KRAS—skin cancer	9.5e-06	0.000195	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HRAS—skin cancer	9.49e-06	0.000195	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—IL6—skin cancer	9.46e-06	0.000194	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HRAS—skin cancer	9.35e-06	0.000192	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTGS2—skin cancer	9.34e-06	0.000192	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—IL6—skin cancer	9.32e-06	0.000191	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTGS2—skin cancer	9.2e-06	0.000189	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SHH—skin cancer	9.08e-06	0.000186	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RASA1—skin cancer	9.02e-06	0.000185	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HRAS—skin cancer	9e-06	0.000184	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—KRAS—skin cancer	8.92e-06	0.000183	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—HRAS—skin cancer	8.87e-06	0.000182	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SHH—skin cancer	8.75e-06	0.000179	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RASA1—skin cancer	8.69e-06	0.000178	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—NRAS—skin cancer	8.66e-06	0.000178	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SMO—skin cancer	8.61e-06	0.000176	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTCH1—skin cancer	8.61e-06	0.000176	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—IL6—skin cancer	8.49e-06	0.000174	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—NRAS—skin cancer	8.49e-06	0.000174	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—KRAS—skin cancer	8.41e-06	0.000172	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—HRAS—skin cancer	8.38e-06	0.000172	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTGER4—skin cancer	8.38e-06	0.000172	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SMO—skin cancer	8.29e-06	0.00017	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTCH1—skin cancer	8.29e-06	0.00017	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HRAS—skin cancer	8.21e-06	0.000168	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—BRAF—skin cancer	8.1e-06	0.000166	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—HRAS—skin cancer	8.08e-06	0.000166	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTGER4—skin cancer	8.07e-06	0.000166	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CSPG4—skin cancer	8.06e-06	0.000165	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—IL6—skin cancer	8.02e-06	0.000164	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—BRAF—skin cancer	7.98e-06	0.000164	CbGpPWpGaD
Afatinib—ERBB2—Immune System—NRAS—skin cancer	7.87e-06	0.000161	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL6—skin cancer	7.86e-06	0.000161	CbGpPWpGaD
Afatinib—ERBB4—Immune System—NRAS—skin cancer	7.75e-06	0.000159	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—IL6—skin cancer	7.73e-06	0.000158	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—NRAS—skin cancer	7.65e-06	0.000157	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—HRAS—skin cancer	7.58e-06	0.000156	CbGpPWpGaD
Afatinib—EGFR—Disease—ERCC2—skin cancer	7.53e-06	0.000154	CbGpPWpGaD
Afatinib—BLK—Immune System—NRAS—skin cancer	7.46e-06	0.000153	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—KRAS—skin cancer	7.45e-06	0.000153	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FOXO4—skin cancer	7.4e-06	0.000152	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—NRAS—skin cancer	7.4e-06	0.000152	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TERT—skin cancer	7.39e-06	0.000152	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—KRAS—skin cancer	7.31e-06	0.00015	CbGpPWpGaD
Afatinib—ERBB2—Disease—NRAS—skin cancer	7.27e-06	0.000149	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—IL6—skin cancer	7.26e-06	0.000149	CbGpPWpGaD
Afatinib—LCK—Disease—ERCC2—skin cancer	7.26e-06	0.000149	CbGpPWpGaD
Afatinib—ERBB4—Disease—NRAS—skin cancer	7.16e-06	0.000147	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—skin cancer	7.15e-06	0.000147	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FOXO4—skin cancer	7.13e-06	0.000146	CbGpPWpGaD
Afatinib—EGFR—Disease—TERT—skin cancer	7.06e-06	0.000145	CbGpPWpGaD
Afatinib—LCK—Hemostasis—NRAS—skin cancer	6.99e-06	0.000143	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6.87e-06	0.000141	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—IL6—skin cancer	6.84e-06	0.00014	CbGpPWpGaD
Afatinib—LCK—Disease—TERT—skin cancer	6.8e-06	0.000139	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KRAS—skin cancer	6.77e-06	0.000139	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KRAS—skin cancer	6.67e-06	0.000137	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KRAS—skin cancer	6.58e-06	0.000135	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—NRAS—skin cancer	6.53e-06	0.000134	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—skin cancer	6.5e-06	0.000133	CbGpPWpGaD
Afatinib—BLK—Immune System—KRAS—skin cancer	6.42e-06	0.000132	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—KRAS—skin cancer	6.37e-06	0.000131	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—skin cancer	6.33e-06	0.00013	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—NRAS—skin cancer	6.3e-06	0.000129	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—NRAS—skin cancer	6.27e-06	0.000129	CbGpPWpGaD
Afatinib—ERBB2—Disease—KRAS—skin cancer	6.25e-06	0.000128	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—skin cancer	6.21e-06	0.000127	CbGpPWpGaD
Afatinib—ERBB4—Disease—KRAS—skin cancer	6.16e-06	0.000126	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	6.11e-06	0.000125	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—skin cancer	6.06e-06	0.000124	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—NRAS—skin cancer	6.05e-06	0.000124	CbGpPWpGaD
Afatinib—LCK—Hemostasis—KRAS—skin cancer	6.02e-06	0.000123	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ERCC2—skin cancer	5.89e-06	0.000121	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—BRAF—skin cancer	5.85e-06	0.00012	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—skin cancer	5.76e-06	0.000118	CbGpPWpGaD
Afatinib—IRAK1—Immune System—NRAS—skin cancer	5.69e-06	0.000117	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—skin cancer	5.67e-06	0.000116	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KRAS—skin cancer	5.62e-06	0.000115	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—skin cancer	5.59e-06	0.000115	CbGpPWpGaD
Afatinib—EGFR—Disease—BRAF—skin cancer	5.59e-06	0.000115	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—skin cancer	5.51e-06	0.000113	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO2—skin cancer	5.48e-06	0.000112	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—skin cancer	5.46e-06	0.000112	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—skin cancer	5.43e-06	0.000111	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—skin cancer	5.42e-06	0.000111	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—skin cancer	5.41e-06	0.000111	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—skin cancer	5.4e-06	0.000111	CbGpPWpGaD
Afatinib—LCK—Disease—BRAF—skin cancer	5.39e-06	0.00011	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—skin cancer	5.35e-06	0.00011	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—skin cancer	5.35e-06	0.00011	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—skin cancer	5.32e-06	0.000109	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—skin cancer	5.24e-06	0.000107	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—skin cancer	5.22e-06	0.000107	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—skin cancer	5.2e-06	0.000107	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—skin cancer	5.18e-06	0.000106	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—skin cancer	5.12e-06	0.000105	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NRAS—skin cancer	5.09e-06	0.000104	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—skin cancer	5.09e-06	0.000104	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NRAS—skin cancer	5.01e-06	0.000103	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—skin cancer	5.01e-06	0.000103	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TERT—skin cancer	4.94e-06	0.000101	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—skin cancer	4.9e-06	0.0001	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—skin cancer	4.78e-06	9.8e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TERT—skin cancer	4.76e-06	9.77e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—skin cancer	4.61e-06	9.44e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—skin cancer	4.59e-06	9.41e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—skin cancer	4.57e-06	9.38e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—skin cancer	4.52e-06	9.26e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NRAS—skin cancer	4.45e-06	9.13e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—skin cancer	4.42e-06	9.07e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—skin cancer	4.41e-06	9.04e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—skin cancer	4.38e-06	8.98e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—skin cancer	4.35e-06	8.92e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—skin cancer	4.31e-06	8.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—NRAS—skin cancer	4.16e-06	8.54e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—skin cancer	4.16e-06	8.54e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—skin cancer	3.98e-06	8.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—skin cancer	3.91e-06	8.03e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—skin cancer	3.89e-06	7.98e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—skin cancer	3.83e-06	7.86e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—skin cancer	3.83e-06	7.86e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NRAS—skin cancer	3.81e-06	7.8e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—skin cancer	3.77e-06	7.74e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—skin cancer	3.72e-06	7.63e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NRAS—skin cancer	3.68e-06	7.54e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—skin cancer	3.67e-06	7.52e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NRAS—skin cancer	3.67e-06	7.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—skin cancer	3.58e-06	7.35e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—skin cancer	3.56e-06	7.31e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—skin cancer	3.53e-06	7.24e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NRAS—skin cancer	3.51e-06	7.2e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—skin cancer	3.51e-06	7.2e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NRAS—skin cancer	3.39e-06	6.94e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—skin cancer	3.27e-06	6.72e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—skin cancer	3.26e-06	6.68e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ERCC2—skin cancer	3.18e-06	6.53e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—skin cancer	3.17e-06	6.49e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—skin cancer	3.16e-06	6.47e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—skin cancer	3.12e-06	6.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—skin cancer	3.05e-06	6.25e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—skin cancer	3.02e-06	6.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—skin cancer	2.92e-06	5.98e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—skin cancer	2.91e-06	5.97e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—skin cancer	2.81e-06	5.77e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—skin cancer	2.78e-06	5.71e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—skin cancer	2.69e-06	5.52e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—skin cancer	2.68e-06	5.5e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—skin cancer	2.66e-06	5.46e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—skin cancer	2.58e-06	5.28e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—skin cancer	2.57e-06	5.27e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—skin cancer	2.57e-06	5.26e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—skin cancer	2.48e-06	5.08e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NRAS—skin cancer	2.46e-06	5.04e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—skin cancer	2.46e-06	5.04e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NRAS—skin cancer	2.37e-06	4.86e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—skin cancer	2.37e-06	4.86e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—skin cancer	2.12e-06	4.34e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—skin cancer	2.04e-06	4.18e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—skin cancer	1.91e-06	3.91e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—skin cancer	1.88e-06	3.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—skin cancer	1.81e-06	3.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—skin cancer	1.8e-06	3.69e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—skin cancer	1.73e-06	3.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—skin cancer	1.72e-06	3.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—skin cancer	1.66e-06	3.4e-05	CbGpPWpGaD
